Category: St. Jude Medical
Some of medtech's largest players, including Medtronic, Johnson & Johnson and Abbott, rank high on the list of companies with the most money housed in offshore tax havens, according to a new report.
There are no awards handed out for companies with the most money housed in overseas accounts, but keeping cash in tax havens is its own reward for at least a dozen top medical device makers, according to a new study.
A federal judge sends a $570 million lawsuit filed against Boston Scientific by the family of Dr. Michel Mirowski, credited with inventing the implantable cardioverter defibrillator, back to a Maryland state court.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
St. Jude Medical says it's complete its $455 million acquisition of CardioMEMS and its Champion HF implantable heart monitor, just days after FDA approval of the device.
St. Jude Medical (NYSE:STJ) wasted no time in closing its acquisition of CardioMEMS, days after the FDA approved the Champion HF implantable heart monitor, saying it plans to begin a "strategic" launch of the device in the U.S.
A look at some of the top medical device companies suggests that the long-lamented medical device tax hasn't had much of an impact on their research & development budgets.
MASSDEVICE ON CALL — Despite repeated warnings and laments, the medical device tax implemented with healthcare reform hasn't appeared to make much of a dent in the industry's research & development activities, according to a small report.
St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.
Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott may look to expand medical device business footprint; Device makers take big writedowns on renal denervation; Cardinal Health closes $320M AccessClosure buy; K2M prices IPO under range at $132M; Allergan board spurns Valeant's $47B offer.
Access Closure Inc.
, Boston Scientific
, Cardinal Health
, Pershing Square Capital Management
, St. Jude Medical
, Valeant Pharmaceuticals
, Abbott Laboratories
, Allergan Inc.